Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. And joining me today is the President and CEO of Vertex Pharmaceuticals, Reshma Kewalramani. Thank you ...
The study presents important insights into the regulation of muscle hypertrophy, regulated by Muscle Ankyrin Repeat Proteins (MARPs) and mTOR. The methods are overall solid and complementary, with ...
Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of ...
Biohaven (BHVN) downgraded after FDA setback for VYGLXIA. Learn key risks, pipeline shifts, and what investors should watch ...
After-tax NPV8 of US$1.1B based on Mineral Reserves TORONTO, ON / ACCESS Newswire / November 6, 2025 / Aclara Resources Inc. ("Aclara" or the ...
After-tax NPV8 of US$1.1B based on Mineral Reserves TORONTO, ON / ACCESS Newswire / November 6, 2025 / Aclara Resources Inc. ("Aclara" or the "Company") is pleased to announce the filing and results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback